Pavao Mark H 4

What Happened
Mark H. Pavao, a director of Coya Therapeutics, was granted a derivative award for 10,000 shares on April 9, 2026. The reported per-share price is $0.00 (no cash paid at grant). This was an award/grant (transaction code A), not a sale—an alignment/compensation event rather than a market transaction.

Key Details

• Transaction date: 2026-04-09 (filing date 2026-04-09). Filing appears timely.
• Shares/units granted: 10,000 derivative shares; reporting shows $0.00 per share at grant.
• Shares owned after transaction: Not specified in the filing.
• Footnote: Award vests 100% on the first anniversary of the grant date, subject to continuous service.
• Transaction type: Derivative award (e.g., RSUs or other equity-based grant); not an exercise or open-market purchase/sale.

Context
A derivative award means the recipient does not receive unrestricted common stock immediately — the award will convert to or become exercisable/vested later (here, one year) if service conditions are met. Such grants are common compensation for directors and senior managers and shouldn't be interpreted alone as a buy or sell signal.